SwePub
Sök i LIBRIS databas

  Extended search

WFRF:(Sandström Lars)
 

Search: WFRF:(Sandström Lars) > (2010-2014) > Imaging of Insulinl...

Imaging of Insulinlike Growth Factor Type 1 Receptor in Prostate Cancer Xenografts Using the Affibody Molecule (111)In-DOTA-Z(IGF1R:4551)

Tolmachev, Vladimir (author)
Uppsala universitet,Enheten för biomedicinsk strålningsvetenskap,Vladimir Tolmachev
Malmberg, Jennie (author)
Uppsala universitet,Plattformen för preklinisk PET,Anna Orlova
Hofström, Camilla (author)
KTH,Molekylär Bioteknologi
show more...
Abrahmsén, Lars (author)
Bergman, Thomas (author)
Sjöberg, Anna (author)
Sandström, Mattias (author)
Uppsala universitet,Enheten för onkologi,Enheten för radiologi
Gräslund, Torbjörn (author)
KTH,Molekylär Bioteknologi
Orlova, Anna (author)
Uppsala universitet,Plattformen för preklinisk PET,Anna Orlova
show less...
 (creator_code:org_t)
2011-12-15
2012
English.
In: Journal of Nuclear Medicine. - : Society of Nuclear Medicine. - 0161-5505 .- 1535-5667 .- 2159-662X. ; 53:1, s. 90-97
  • Journal article (peer-reviewed)
Abstract Subject headings
Close  
  • One of the pathways leading to androgen independence in prostate cancer involves upregulation of insulinlike growth factor type 1 receptor (IGF-1R). Radionuclide imaging of IGF-1R in tumors might be used for selection of patients who would most likely benefit from IGF-1R-targeted therapy. The goal of this study was to evaluate the feasibility of in vivo radionuclide imaging of IGF-1R expression in prostate cancer xenografts using a small nonimmunoglobulin-derived binding protein called an Affibody molecule. Methods: The IGF-1R-binding Z(IGF1R:4551) Affibody molecule was site-specifically conjugated with a maleimido derivative of DOTA and labeled with (111)In. The binding of radiolabeled Z(IGF1R:4551) to IGF-1R-expressing cells was evaluated in vitro and in vivo. Results: DOTA-Z(IGF1R:4551) can be stably labeled with (111)In with preserved specific binding to IGF-1R-expressing cells in vitro. In mice, (111)In-DOTAZ(IGF1R):(4551) accumulated in IGF-1R-expressing organs (pancreas, stomach, lung, and salivary gland). Receptor saturation experiments demonstrated that targeting of DU-145 prostate cancer xenografts in NMRI nu/nu mice was IGF-1R-specific. The tumor uptake was 1.1 +/- 0.3 percentage injected dose per gram, and the tumor-to-blood ratio was 3.2 +/- 0.2 at 8 h after injection. Conclusion: This study demonstrates the feasibility of in vivo targeting of IGF-1R-expressing prostate cancer xenografts using an Affibody molecule. Further development of radiolabeled Affibody molecules might provide a useful clinical tool for stratification of patients with prostate cancer for IGF-1R-targeting therapy.

Subject headings

NATURVETENSKAP  -- Biologi -- Biokemi och molekylärbiologi (hsv//swe)
NATURAL SCIENCES  -- Biological Sciences -- Biochemistry and Molecular Biology (hsv//eng)

Keyword

Affibody molecule
(111)In
molecular imaging
IGF-1R
DU145 xenograft

Publication and Content Type

ref (subject category)
art (subject category)

Find in a library

To the university's database

Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.

 
pil uppåt Close

Copy and save the link in order to return to this view